Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult : SC Palliation of prostatic carcinoma 3.6 mg every 28 days or 10.8 mg every 12 wk. Pituitary desensitisation before ovulation induction w/ gonadotrophins Depot 3.6 mg.
Dosage Details
Palliative treatment of prostatic carcinoma
Adult: 3.6 mg injected into the anterior abdominal wall every 28 days or 10.8 mg every 12 wk. An anti-androgen is given several days before beginning of the treatment and continued for at least 3 wk to prevent disease flare.

Pituitary desensitisation before ovulation induction with gonadotrophins
Adult: 3.6 mg as a depot inj. Monitor serum-oestradiol concentrations until they decline to levels similar to those in the early follicular phase which takes about 7-21 days.
Hypersensitivity; pregnancy, lactation.
Special Precautions
Urinary tract obstruction or spinal cord compression (when used for prostate cancer); decreased bone density in women. Contraceptive measures should be taken to protect against pregnancy. Monitor men at risk from tumour flare during the 1st mth of therapy. Safety and efficacy on the usage of the 10.8 mg implant in women is not established.
Adverse Reactions
Vaginal bleeding and dryness, arthralgia, paraesthesias, increase in menstrual bleeding, hot flushes, sexual dysfunction. Headache, emotional lability, depression, insomnia, diaphoresis, dizziness, breast swelling/tenderness, Inj site reactions. Anaphylaxis.
SC: X (In patients w/ endometriosis & endometrial thinning), D (In patients w/ advanced breast cancer)
Description: Goserelin is a potent inhibitor of pituitary gonadotrophin secretion. Initially, it causes an increase in the serum levels of FSH and LH but chronic admin will lead to sustained suppression of the pituitary gonadotrophin release causing regression of the sex organs.
Absorption: Almost complete (SC).
Excretion: >90% excreted in urine (as unchanged drug and metabolites); 2-4 hr (elimination half-life).
Store below 25°C.
Disclaimer: This information is independently developed by MIMS based on Goserelin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in